<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05623878</url>
  </required_header>
  <id_info>
    <org_study_id>LS2020005</org_study_id>
    <nct_id>NCT05623878</nct_id>
  </id_info>
  <brief_title>68Ga-labeled NY108 PET Imaging in Patients</brief_title>
  <official_title>68Ga-labeled NY108 PET Imaging in Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Hospital of Jiangnan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Hospital of Jiangnan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm study to evaluate the safety and biodistribution of 68Ga-labeled NY108&#xD;
      (68Ga-NY108) PET Imaging in patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2022</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of tissue distribution of 68Ga-Anti-PSMA mAbs(NY108)</measure>
    <time_frame>1 year</time_frame>
    <description>Biodistribution of 68Ga-Anti-PSMA mAbs(NY108) evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 68Ga-PET scans will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>Safety will be assessed by evaluation of incidence of adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostatic Cancer</condition>
  <arm_group>
    <arm_group_label>68Ga-Anti-PSMA mAbs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-labeled NY108</intervention_name>
    <description>Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY108.</description>
    <arm_group_label>68Ga-Anti-PSMA mAbs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients voluntarily signed informed consent;&#xD;
&#xD;
          2. Age 18-75, male;&#xD;
&#xD;
          3. Patients diagnosed with prostatic cancer confirmed by histopathology or cytology;&#xD;
&#xD;
          4. At least one measurable solid lesion has been examined according RECIST1.1 standard;&#xD;
&#xD;
          5. Patients with biopsy-proven PSMA positive;&#xD;
&#xD;
          6. ECOG score 0~3; Life expectancy of at least 3 months;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recovery from major trauma (including surgery) within 4 weeks prior to study&#xD;
             treatment;&#xD;
&#xD;
          2. Patients with systemic or locally severe infections, or other serious coexisting&#xD;
             diseases;&#xD;
&#xD;
          3. Patients with allergies or allergies to any component of the imaging agent or&#xD;
             antibody;&#xD;
&#xD;
          4. Patients who cannot perform PET/CT imaging scan;&#xD;
&#xD;
          5. Patients with abnormal immune function or who have recently used immunosuppressive or&#xD;
             potentiating agents including various vaccines;&#xD;
&#xD;
          6. Patients with autoimmune diseases, including rheumatoid arthritis; Inadequate control&#xD;
             of arrhythmias, including atrial fibrillation;&#xD;
&#xD;
          7. Uncontrolled hypertension;&#xD;
&#xD;
          8. Syphilis, HBV, HCV, or HIV positive subjects;&#xD;
&#xD;
          9. Male subjects of reproductive age cannot take effective contraceptive measures;&#xD;
&#xD;
         10. Patients with a history of mental illness or related conditions;&#xD;
&#xD;
         11. Other subjects considered unsuitable by researchers.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunjing Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Hospital of Jiangnan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunjing Yu</last_name>
    <phone>15312238622</phone>
    <email>ycj_wxd1978@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangnan University</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunjing Yu</last_name>
      <phone>15312238622</phone>
      <email>ycj_wxd1978@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 15, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2022</study_first_posted>
  <last_update_submitted>November 27, 2022</last_update_submitted>
  <last_update_submitted_qc>November 27, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Affiliated Hospital of Jiangnan University</investigator_affiliation>
    <investigator_full_name>Chunjing Yu</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

